SI1551370T1 - Agregat s povečano deformabilnostjo, ki obsega vsaj tri amfipatične snovi, za izboljšanje transporta skozi polprepustne pregrade in za neinvazivnodajanje zdravila in vivo, posebno skozi kožo - Google Patents

Agregat s povečano deformabilnostjo, ki obsega vsaj tri amfipatične snovi, za izboljšanje transporta skozi polprepustne pregrade in za neinvazivnodajanje zdravila in vivo, posebno skozi kožo

Info

Publication number
SI1551370T1
SI1551370T1 SI200331142T SI200331142T SI1551370T1 SI 1551370 T1 SI1551370 T1 SI 1551370T1 SI 200331142 T SI200331142 T SI 200331142T SI 200331142 T SI200331142 T SI 200331142T SI 1551370 T1 SI1551370 T1 SI 1551370T1
Authority
SI
Slovenia
Prior art keywords
application
invasive
aggregate
vivo
skin
Prior art date
Application number
SI200331142T
Other languages
English (en)
Slovenian (sl)
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of SI1551370T1 publication Critical patent/SI1551370T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200331142T 2002-10-11 2003-10-09 Agregat s povečano deformabilnostjo, ki obsega vsaj tri amfipatične snovi, za izboljšanje transporta skozi polprepustne pregrade in za neinvazivnodajanje zdravila in vivo, posebno skozi kožo SI1551370T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (1)

Publication Number Publication Date
SI1551370T1 true SI1551370T1 (sl) 2008-06-30

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331142T SI1551370T1 (sl) 2002-10-11 2003-10-09 Agregat s povečano deformabilnostjo, ki obsega vsaj tri amfipatične snovi, za izboljšanje transporta skozi polprepustne pregrade in za neinvazivnodajanje zdravila in vivo, posebno skozi kožo

Country Status (21)

Country Link
EP (5) EP1815846A3 (enExample)
JP (3) JP2006505619A (enExample)
KR (1) KR20050055723A (enExample)
CN (1) CN1703199B (enExample)
AT (1) ATE381316T1 (enExample)
AU (1) AU2003273977B2 (enExample)
BR (1) BR0315148A (enExample)
CA (1) CA2498938A1 (enExample)
DE (1) DE60318227T2 (enExample)
DK (1) DK1551370T3 (enExample)
EA (1) EA010407B1 (enExample)
ES (1) ES2298566T3 (enExample)
HR (1) HRPK20050421B3 (enExample)
IS (1) IS7776A (enExample)
MX (1) MXPA05003744A (enExample)
NO (1) NO20052281L (enExample)
NZ (1) NZ538571A (enExample)
PL (1) PL377202A1 (enExample)
PT (1) PT1551370E (enExample)
SI (1) SI1551370T1 (enExample)
WO (1) WO2004032900A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
CA2698293A1 (en) * 2007-09-13 2009-03-26 Thomas Subkowski Use of hydrophobin polypeptides as penetration intensifiers
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
JP2012528846A (ja) * 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2688554A2 (en) * 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
US20140017301A1 (en) * 2011-03-21 2014-01-16 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
JP6375301B2 (ja) * 2012-10-26 2018-08-15 オックスフォード ナノポール テクノロジーズ リミテッド 液滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
SG11201600424VA (en) * 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
CN105658782B (zh) * 2013-10-25 2018-08-07 凸版印刷株式会社 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
CN110662532A (zh) * 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
CZ20012038A3 (cs) * 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers

Also Published As

Publication number Publication date
ATE381316T1 (de) 2008-01-15
EP1815846A2 (en) 2007-08-08
NO20052281L (no) 2005-07-07
JP2006505619A (ja) 2006-02-16
JP2005213261A (ja) 2005-08-11
NO20052281D0 (no) 2005-05-10
NZ538571A (en) 2007-05-31
EP1829527A2 (en) 2007-09-05
HK1079113A1 (en) 2006-03-31
ES2298566T3 (es) 2008-05-16
EA200500632A1 (ru) 2005-12-29
IS7776A (is) 2005-03-30
BR0315148A (pt) 2005-08-16
EP1829527A3 (en) 2008-11-05
MXPA05003744A (es) 2005-09-20
HRPK20050421B3 (en) 2007-06-30
EA010407B1 (ru) 2008-08-29
PT1551370E (pt) 2008-02-07
PL377202A1 (pl) 2006-01-23
DE60318227T2 (de) 2008-12-04
CN1703199B (zh) 2010-04-28
EP1551370B1 (en) 2007-12-19
JP4555111B2 (ja) 2010-09-29
CA2498938A1 (en) 2004-04-22
EP1815847A2 (en) 2007-08-08
DE60318227D1 (de) 2008-01-31
EP1551370A1 (en) 2005-07-13
HRP20050421A2 (en) 2005-12-31
AU2003273977B2 (en) 2007-07-12
KR20050055723A (ko) 2005-06-13
WO2004032900A8 (en) 2005-03-31
CN1703199A (zh) 2005-11-30
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
AU2003273977A1 (en) 2004-05-04
EP1829528A3 (en) 2008-11-05
EP1815847A3 (en) 2008-11-05
WO2004032900A1 (en) 2004-04-22
EP1815846A3 (en) 2008-10-22
JP2009108070A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
NO20052281D0 (no) Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
ATE89717T1 (de) Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff.
RU2005138915A (ru) Сульфонамид замещенные имидазохинолины
NO174326C (no) Anvendelse av målsökende merket polypeptid
JP2004536045A5 (enExample)
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
SE9901972D0 (sv) Metod, anordning och användning vid implantat för att tillförsäkra tillförsel av bioaktiv substans till implantatets omgivande ben och/eller vävnad
ATE341461T1 (de) Kipperfahrzeug
EP1295611A4 (en) COMPOUNDS FOR THE TRANSFER OF OLIGONUCLEOTIDES (03.01.02)
EP1722635A4 (en) FEEDSTUFFS CONTAINING HOPFIC ACIDS AND THEIR USE AS ANIMAL FEED ADDITIVES
CN106170261A (zh) 悬浮未输送颗粒的液体媒介
WO2003072606A3 (en) Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
CN108348609A (zh) 用于光动力学疗法的金丝桃素配制剂
Labi et al. The Grief Brigade.
Derynck et al. Cell differentiation
DK0637956T3 (da) Anvendelse af remacemid til behandling af Parkinsonˆs sygdom
AR067345A1 (es) Uso de trombomodulina para la preparacion de un medicamento trombolitico
Kryzyna et al. State management issues on health care in dissertations defended in 2005
AU2001288169A1 (en) Use of oligomers of hyaluronan for the treatment of an in vitro fertilised embryo and for the denudation of an oocyte before fertilisation
AR026988A1 (es) Composicion para mejorar la respuesta proliferativa durante la adaptacion del tracto gastrointestinal y uso en el sindrome de intestino corto
WO2002000170A3 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
Zhang et al. Experimental study on microvascular architecture of human and rabbit flaps with two methods
ES2112822T1 (es) Procedimiento para la preparacion de cefalosporinas.